acute myelogenous leukemia
Conditions
Interventions
ABC-14 regimen:Chidamide?Venetoclax?Azacitidine
AB-14 regimen:Azacitidine?Venetoclax
"3+7" Standard Induction Therapy:Daunorubicin or Idarubicin or mitoxantrone, cytarabine
Sponsors
Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Diagnosed with AML (diagnostic criteria refer to WHO 2022 standards, not APL), has not received systemic anti-leukemia treatment (except for tumor-reducing pretreatment such as hydroxyurea, low-dose cytarabine, etc.); 2. Age >= 18 years; 3. ECOG <= 4; 4. Women of childbearing potential agree to take effective contraceptive measures during the treatment period and for 3 months after treatment ends; 5. Signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Known history of allergy to the investigational drug; 2.Resistance to Azacytidine, Venetoclax or Chidamide; 3.Inability to take oral medication; 4.Combined with uncontrolled active infections (including bacterial, fungal or viral infections); 5.Combined with uncontrolled major organ dysfunction: cardiac insufficiency, decompensated liver insufficiency, moderate/severe renal insufficiency, etc. 6.Participating in other clinical studies that affect the main purpose of this study; 7.Patients deemed unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite complete remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| Minor residual disease (MRD) negative rate;Duration of remission, DoR;1-year recurrence-free survival rate;1 year overall survival rate; | — |
Countries
China
Contacts
Public ContactDu Xin; Weng Jianyu
Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences)
Outcome results
None listed